Editorials

Why Do Patients With Systemic Lupus Erythematosus Suffer Pain?
Anisur Rahman .................................................. 1195

Transition Between Treatments: What We Need to Know
Kirsten Minden, Jens Klotsche ................................. 1198

The COVID-19 Vaccine Landscape: What a Rheumatologist Needs to Know
Katie Bechman, Mrinalini Dey, Mark Yates,
Marwan Bukhari, Kevin Winthrop,
James B. Galloway .................................................. 1201

Rethinking Physical Activity Promotion During the COVID-19 Pandemic: Focus on a 24-hour Day
Linda C. Li, Lynne M. Feehan, Alison M. Hoens .............. 1205

Review

Nail Psoriasis: Diagnosis, Assessment, Treatment Options, and Unmet Clinical Needs
Gurjit S. Kaeley, Lihi Eder, Sibel Zehra Aydin,
Phoebe Rich, Catherine J. Bakewell ......................... 1208

Rheumatoid Arthritis

Impact of Comorbid Conditions on Healthcare Expenditure and Work-related Outcomes in Patients With Rheumatoid Arthritis
Martin Vu, Natalie Carvalho, Philip M. Clarke,
Rachelle Buchbinder, An Tran-Duy ............................... 1221

Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs
Arthur Kavanaugh, Rene R. Westhovens,
Kevin L. Winthrop, et al ........................................... 1230

Meaningful Change Thresholds for Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue and Pain Interference Scores in Patients With Rheumatoid Arthritis
Jennifer L. Beaumont, Elizabeth S. Davis,
Jeffrey R. Curtis, David Cella, Huiying Yun .................. 1239

Tuberculosis in Biologic-naïve Patients With Rheumatoid Arthritis: Risk Factors and Tuberculosis Characteristics
Johanna Karlsson Sundbaum, Elizabeth V. Arkema,
Judith Bruchfeld, Jerker Jonsson, Johan Askling,
Eva Baecklund ......................................................... 1243

Spondyloarthritis

Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase III Studies
Georg Schett, Xenofon Baraliakos,
Filip Van den Bosch, et al ............................................ 1251

A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis
Peter C. Taylor, Désirée van der Heijde, Robert Landewé,
Shannon McCue, Sue Cheng, Annelies Boonen ............. 1259

Psoriatic Arthritis

Evaluation and Validation of a Patient-completed Psoriatic Arthritis Flare Questionnaire
Philip S. Helliwell, William Tillett, Robin Waxman, et al,
on behalf of the PROMPT Study Group ......................... 1268

Comparison of Composite Measure Remission Targets in Psoriatic Arthritis
Flora Farkas, Natsumi Ikumi, Musaab Elmamoun,
Agnes Szentpetery, Oliver FitzGerald ........................... 1272

Systemic Lupus Erythematosus

The Problem of Pain in Systemic Lupus Erythematosus: An Explication of the Role of Biopsychosocial Mechanisms
Titilola Falasinnu, Cristina Drenkard, Gaobin Bao,
Sean Mackey, S. Sam Lim ........................................... 1279

Sjögren Syndrome

Correlation Between Subjective and Objective Severity of Oral and Ocular Dryness in Primary Sjögren Syndrome
David A. Ripsman, Arthur A.M. Bookman ..................... 1290

Open Access article

Contents continued on page x